Coagulation Biomarkers
Target engagement of garadacimab was shown by an increase and prolongation of aPTT to Day 14 (Fig. Boxplots of aPTT in the ITT population. *n (%) shows the number (%) of subjects who had aPTT values above the ULOQ in the respective treatment group at the given visit. 